Regeneron (REGN) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Regeneron Pharma (REGN) Price Target Raised to $410 at RBC
November 4, 2014 3:28 PM ESTRBC Capital maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $410.00 (from $373.00). Comments follow Q3 results. Analyst Adnan Butt said he was a buyer of pullbacks.
"While ramp from DME did not materialize, the... More
Regeneron Pharma (REGN) Price Target Raised to $455 at Deutsche Bank
November 4, 2014 1:39 PM ESTDeutsche Bank reiterated a Buy rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $455.00 (from $425.00). The change follows Q3 results. Analyst Robyn Karnauskas sees major upside in the stock next year.
"Eylea US sales for 3Q missed expectations at... More
